LEXINGTON, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has achieved the first two development milestones under its agreement with The Leukemia & Lymphoma Society (LLS) for the development of CUDC-907, a first-in-class orally-administered small molecule drug candidate inhibitor of phosphatidylinositol-3-kinase (PI3K) and histone deacetylase (HDAC). These milestones include a preclinical development objective, as well as Curis’ recent filing of an Investigational New Drug (IND) application to begin Phase I clinical testing of CUDC-907 in patients. As a result, Curis will receive $750,000 in milestone payments under the terms of its agreement with LLS.
